Global Finance News
19 Aug 2026, 16:51
Ryan Specialty Stock Rises 2.9% as Morgan Stanley Raises Price Target to $50
Ryan Specialty (NYSE: RYAN) shares are up about 2.9% after Morgan Stanley raised its price target on the specialty insurance company while maintaining an Overweight rating.
Morgan Stanley analyst Bob Huang increased the firm's price target to $50 from $48. Compared with the stock's current price of $42.42, the new target implies approximately 18% upside.
Ryan Specialty holds a strong position in the specialty insurance distribution market, providing wholesale brokerage and underwriting management services for complex or difficult-to-place risks. The company benefits from growing demand for specialty insurance as businesses face increasingly complex exposures that are often underserved by traditional insurance markets.
Its largely fee- and commission-based model also provides recurring revenue without assuming the same level of underwriting risk as an insurance carrier.
The 2.9% gain suggests investors are responding positively to Morgan Stanley's higher valuation outlook and reiterated Overweight rating, reinforcing confidence in Ryan Specialty's position within the growing specialty insurance sector.
Ryan Specialty (NYSE: RYAN) shares are up about 2.9% after Morgan Stanley raised its price target on the specialty insurance company while maintaining an Overweight rating.
Morgan Stanley analyst Bob Huang increased the firm's price target to $50 from $48. Compared with the stock's current price of $42.42, the new target implies approximately 18% upside.
Ryan Specialty holds a strong position in the specialty insurance distribution market, providing wholesale brokerage and underwriting management services for complex or difficult-to-place risks. The company benefits from growing demand for specialty insurance as businesses face increasingly complex exposures that are often underserved by traditional insurance markets.
Its largely fee- and commission-based model also provides recurring revenue without assuming the same level of underwriting risk as an insurance carrier.
The 2.9% gain suggests investors are responding positively to Morgan Stanley's higher valuation outlook and reiterated Overweight rating, reinforcing confidence in Ryan Specialty's position within the growing specialty insurance sector.